Engineering immune cell engagers: From molecular constructs to biomaterial platforms.
- 1Immuno-Oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, 10408, Republic of Korea.
Abstract
Immune cell engagers (ICEs) are emerging therapeutic platforms that redirect immune effector cells toward cancer cells by physically bridging immune-cell receptors with tumor-associated targets. This cell-bridging mechanism converts molecular recognition into localized immune activation, immune synapse formation, cytotoxic killing, or phagocytic clearance. Such contact-centered immune redirection complements immune checkpoint blockade, which can restore antitumor immunity but does not directly promote the physical immune cell-tumor cell contact required for productive effector functions. Building on this principle, advances in molecular and biomaterial engineering have expanded ICE design beyond conventional molecular formats, enabling programmable molecular bridges, engineered living cell surfaces, and material-scaffolded systems that coordinate tumor targeting, immune-cell recruitment, and functional modulation. In this review, we organized these approaches according to three levels of ICE engineering: (1) molecular ICEs such as engineered antibodies and aptamers, (2) living cell engagers based on cell surface engineering using molecular constructs or biomaterials and (3) nanoparticle platforms. Across these platforms, we discuss molecular architecture, tumor-targeting specificity, immune cell recruitment, and functional modulation as key factors governing direct immune-tumor cell interactions. By connecting diverse strategies through a common cell-engagement perspective, this review highlights how these approaches can provide functional and spatial advantages for next-generation cancer immunotherapy.
Related
- Advanced molecular poliovirus diagnostics across multiple real-time PCR platforms with locked nucleic acids and primer overhangs
- 627 An innovative approach to improve bispecific T-cell engagers for solid tumor therapy
- Bispecific VSV-G Engagers: A Platform for Cell-Type-Specific Delivery of Viral Vectors
- Engineering Wheat for Compound Climate Extremes: Molecular Trade-Offs, Stress Memory, and Precision Genome Editing for Yield-Stable Resilience
- Molecular engineering of a therapeutic antibody for Blo t 5–induced allergic asthma
BibTeX
@article{park2026engineering,
title = {{Engineering immune cell engagers: From molecular constructs to biomaterial platforms.}},
author = {Hee Won Park and Sungjun Kim},
journal = {Materials today. Bio},
year = {2026},
month = oct,
doi = {10.1016/j.mtbio.2026.103737},
url = {https://europepmc.org/article/MED/42898667},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Engineering immune cell engagers: From molecular constructs to biomaterial platforms.
AU - Hee Won Park
AU - Sungjun Kim
PY - 2026
DA - 2026/10/07
JO - Materials today. Bio
DO - 10.1016/j.mtbio.2026.103737
UR - https://europepmc.org/article/MED/42898667
AB - Immune cell engagers (ICEs) are emerging therapeutic platforms that redirect immune effector cells toward cancer cells by physically bridging immune-cell receptors with tumor-associated targets. This cell-bridging mechanism converts molecular recognition into localized immune activation, immune synapse formation, cytotoxic killing, or phagocytic clearance. Such contact-centered immune redirection complements immune checkpoint blockade, which can restore antitumor immunity but does not directly promote the physical immune cell-tumor cell contact required for productive effector functions. Building on this principle, advances in molecular and biomaterial engineering have expanded ICE design beyond conventional molecular formats, enabling programmable molecular bridges, engineered living cell surfaces, and material-scaffolded systems that coordinate tumor targeting, immune-cell recruitment, and functional modulation. In this review, we organized these approaches according to three levels of ICE engineering: (1) molecular ICEs such as engineered antibodies and aptamers, (2) living cell engagers based on cell surface engineering using molecular constructs or biomaterials and (3) nanoparticle platforms. Across these platforms, we discuss molecular architecture, tumor-targeting specificity, immune cell recruitment, and functional modulation as key factors governing direct immune-tumor cell interactions. By connecting diverse strategies through a common cell-engagement perspective, this review highlights how these approaches can provide functional and spatial advantages for next-generation cancer immunotherapy.
SN - 2590-0064
ER -